FOLD News and Press, Amicus Therapeutics Inc.

2026-03-09 09:25:56 ET On Feb. 13, 2026, Rice Hall James & Associates, LLC disclosed a buy of QuidelOrtho (NASDAQ:QDEL) in the fourth quarter. An SEC filing dated Feb. 13, 2026, shows Rice Hall James & Associates, LLC bought 574,877 shares of QuidelOrtho during the f...

2026-03-09 08:44:17 ET Rice Hall James & Associates, LLC disclosed a buy of 122,430 shares of Stride (NYSE:LRN) in the fourth quarter. According to a Securities and Exchange Commission (SEC) filing dated Feb. 13, 2026, Rice Hall James & Associates, LLC increased its ...

2026-02-20 16:10:08 ET More on Amicus Therapeutics BioMarin Acquiring Amicus -- Both Great Companies, Only One Worth Buying Now BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight Key deals this week: Trump Media & Technology, Howard Hughes, BioMa...

2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq...

OGE Energy Corp (OGE) is expected to report $0.3 for Q4 2025 Dana Incorporated (DAN) is expected to report $0.32 for Q4 2025 SiriusPoint Ltd. (SPNT) is expected to report $0.54 for Q4 2025 Nutrien Ltd. (NTR) is expected to report $0.82 for Q4 2025 Broadstone Net Lease Inc. (BNL) i...

PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold ® (migalastat) in Fabry disease and POMBILITI ® + OPFOLDA ® (cipaglucosidase alfa plus miglust...

2026-02-01 06:17:13 ET Shares of rare disease concern BioMarin Pharmaceuticals Inc. ( BMRN ) initially rallied nicely after announcing its intention to acquire model portfolio holding Amicus Therapeutics ( FOLD ) for $4.8 billion on December 19th. The acquisition deliver...

2026-01-26 09:19:21 ET Fast Facts About the Direxion Daily S&P Biotech Bear 3x Shares ETF Read the full article on Seeking Alpha For further details see: LABD: ETF To Benefit From Downturns In The Biotech Industry

2026-01-22 05:04:58 ET Dennis Ding from Jefferies issued a price target of $14.50 for FOLD on 2026-01-22 08:11:00. The adjusted price target was set to $14.50. At the time of the announcement, FOLD was trading at $14.35. The overall price target consensus is at $14.25 wi...

2026-01-10 11:00:00 ET Get ahead of the market by subscribing to Seeking Alpha's Wall Street Week Ahead, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings re...